William Blair Investment Management LLC reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 33.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,454,117 shares of the company’s stock after selling 720,477 shares during the period. Twist Bioscience makes up about 0.9% of William Blair Investment Management LLC’s investment portfolio, making the stock its 13th biggest position. William Blair Investment Management LLC owned approximately 2.32% of Twist Bioscience worth $280,994,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Western Wealth Management LLC acquired a new stake in Twist Bioscience during the 1st quarter worth $31,000. Root Financial Partners LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at $33,000. PNC Financial Services Group Inc. lifted its stake in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period. Fifth Third Bancorp acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $54,000. Finally, Allworth Financial LP acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at $62,000.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. Robert W. Baird reduced their price target on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday. Jefferies Financial Group set a $125.00 price objective on Twist Bioscience in a report on Thursday. BWS Financial reissued a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a research note on Friday, September 18th. Guggenheim raised their target price on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, Barclays raised their target price on Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $141.00.
Get Our Latest Research Report on Twist Bioscience
Twist Bioscience Stock Performance
TWST stock opened at $111.60 on Monday. The business’s 50-day moving average price is $150.23 and its two-hundred day moving average price is $93.07. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The firm has a market cap of $7.00 billion, a PE ratio of -53.40 and a beta of 2.25. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $126.64 million during the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The firm’s revenue for the quarter was up 26.7% compared to the same quarter last year. As a group, research analysts forecast that Twist Bioscience Corporation will post -1.52 earnings per share for the current year.
Insiders Place Their Bets
In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the sale, the insider directly owned 63,789 shares in the company, valued at approximately $12,048,466.32. This trade represents a 12.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the transaction, the senior vice president directly owned 106,632 shares in the company, valued at approximately $20,140,652.16. The trade was a 8.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 495,279 shares of company stock valued at $80,489,387 over the last 90 days. 3.08% of the stock is owned by company insiders.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Further Reading
- Five stocks we like better than Twist Bioscience
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
